BR112023025235A2 - Compostos de indol substituídos e métodos de uso dos mesmos - Google Patents

Compostos de indol substituídos e métodos de uso dos mesmos

Info

Publication number
BR112023025235A2
BR112023025235A2 BR112023025235A BR112023025235A BR112023025235A2 BR 112023025235 A2 BR112023025235 A2 BR 112023025235A2 BR 112023025235 A BR112023025235 A BR 112023025235A BR 112023025235 A BR112023025235 A BR 112023025235A BR 112023025235 A2 BR112023025235 A2 BR 112023025235A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
substituted indol
inhibitors
complement
Prior art date
Application number
BR112023025235A
Other languages
English (en)
Inventor
P Bestvater Brian
Andrew Powell David
Jinyue Ding
Anton MATEYKO Nicholas
Robert Gomez
Tao Sheng
Taro Oike
Elizabeth ROSE Victoria
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of BR112023025235A2 publication Critical patent/BR112023025235A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

compostos de indol substituídos e métodos de uso dos mesmos. a presente invenção refere-se a compostos de indol substituídos. em certas concretizações, os compostos são inibidores da via alternativa do sistema complemento e, em particular, inibidores do fator de complemento b (cfb). são também proporcionadas composições compreendendo os compostos e métodos de utilização dos mesmos. os compostos fornecidos são úteis no tratamento, prevenção ou melhoria de uma doença, condição ou distúrbio através da inibição da via alternativa do complemento.
BR112023025235A 2021-06-03 2022-06-03 Compostos de indol substituídos e métodos de uso dos mesmos BR112023025235A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163196339P 2021-06-03 2021-06-03
US202163290019P 2021-12-15 2021-12-15
US202263346120P 2022-05-26 2022-05-26
PCT/US2022/032042 WO2022256586A2 (en) 2021-06-03 2022-06-03 Substituted indole compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023025235A2 true BR112023025235A2 (pt) 2024-02-27

Family

ID=84323595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025235A BR112023025235A2 (pt) 2021-06-03 2022-06-03 Compostos de indol substituídos e métodos de uso dos mesmos

Country Status (15)

Country Link
US (1) US20240287034A1 (pt)
EP (1) EP4346812A2 (pt)
JP (1) JP2024521878A (pt)
KR (1) KR20240017004A (pt)
AU (1) AU2022283903A1 (pt)
BR (1) BR112023025235A2 (pt)
CA (1) CA3222144A1 (pt)
CL (1) CL2023003591A1 (pt)
CO (1) CO2023016557A2 (pt)
CR (1) CR20230564A (pt)
DO (1) DOP2023000263A (pt)
EC (1) ECSP23090260A (pt)
IL (1) IL308835A (pt)
MX (1) MX2023014274A (pt)
WO (1) WO2022256586A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072197A1 (en) * 2021-10-27 2023-05-04 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
IL314186A (en) * 2022-01-24 2024-09-01 Novartis Ag PIPERIDINYL SPIROCYCLIC DERIVATIVES AS COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF
WO2023237012A1 (zh) * 2022-06-07 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸类氘代化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
TW202426432A (zh) * 2022-09-10 2024-07-01 大陸商江蘇豪森藥業集團有限公司 ２－取代哌啶衍生物、其製備方法和醫藥用途
WO2024104292A1 (en) * 2022-11-14 2024-05-23 Novartis Pharma Ag Solid forms of complement factor b inhibitors
WO2024114677A1 (zh) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
WO2024149261A1 (zh) * 2023-01-09 2024-07-18 南京正大天晴制药有限公司 补体因子b抑制剂
WO2024169896A1 (zh) * 2023-02-16 2024-08-22 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物的盐、晶型及其在医药上的应用
WO2024175028A1 (zh) * 2023-02-22 2024-08-29 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物的药物组合物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014002054A1 (en) * 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EP3448389B1 (en) * 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
AU2021323300A1 (en) * 2020-08-07 2023-04-06 Shanghai Meiyue Biotech Development Co., Ltd. Complement factor B inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof

Also Published As

Publication number Publication date
CL2023003591A1 (es) 2024-06-28
JP2024521878A (ja) 2024-06-04
CR20230564A (es) 2024-02-27
MX2023014274A (es) 2024-04-22
WO2022256586A2 (en) 2022-12-08
DOP2023000263A (es) 2024-02-29
US20240287034A1 (en) 2024-08-29
KR20240017004A (ko) 2024-02-06
AU2022283903A1 (en) 2023-11-30
CO2023016557A2 (es) 2024-02-26
EP4346812A2 (en) 2024-04-10
WO2022256586A3 (en) 2023-01-12
IL308835A (en) 2024-01-01
CA3222144A1 (en) 2022-12-08
ECSP23090260A (es) 2024-02-29

Similar Documents

Publication Publication Date Title
BR112023025235A2 (pt) Compostos de indol substituídos e métodos de uso dos mesmos
CL2020001133A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BRPI0517737A (pt) inibidores de quinase
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112021020709A2 (pt) Métodos para administração de certos inibidores de vmat2
Wayne et al. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
BR112021022380A2 (pt) Inibidores de jak
BR112022000855A2 (pt) Moduladores de nlrp3
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CY1110415T1 (el) Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs)
BR112022006608A2 (pt) Inibidores orais do fator d do complemento
BR112021020424A2 (pt) Compostos e métodos para tratamento de distúrbios inflamatórios
BR112021014566A2 (pt) Moduladores de gpr35